TreatmentTreatment of Chronic hepatitis caused by hepatitis-B
• Product name: Telarfe
Common name: Tenofovir alafenamide.
Trafene is a hepatitis B virus (HBV) nucleoside analog reverse transcriptase inhibitor used for treatment
Adult patients with chronic hepatitis B virus (HBV) infection with compensated liver disease.
Dose and administration method
1. Method of administration
- Test: Before starting to take Trafen, test the patient for HIV infection. People with HIV infection should not
Use Trafen alone. In addition, before and during treatment, it is recommended to perform the following according to clinical needs
Detection: serum creatinine, serum phosphorus, creatinine clearance, urine glucose and urine protein.
- Recommended dose: 25mg (one tablet), taken with food, once a day.
- Renal impairment: It is not recommended for patients whose estimated creatinine clearance rate is less than 15 ml per minute.
- Hepatic impairment: It is not recommended for patients with decompensated (Child-Pugh B or C) hepatic impairment.
2. Dosage specifications
- Tablets, 25 mg of tenofovir alafenamide (trafene).
3. Contraindications: None.
Warnings and Precautions
- Co-infection of HBV and HIV-1: It is not recommended to use Trafene alone as a treatment for HIV-1 infection, because It may lead to HIV-1 drug resistance.
- New or worsening renal impairment: Before starting to take Trafen The bed assesses serum creatinine and serum phosphorus levels, estimates creatinine clearance, urine glucose and urine protein.
The most common adverse reactions (incidence rate ≥5%, all grades) include: headache, abdominal pain, fatigue, cough, nausea, and back pain.
Store below 30°C (86°F).